Supplementary materials




Figure S1. Trial profile. (A) Study CHN. (B) Study AUS. * Two subjects (one each in 2 and 20 mg/kg SHR-1707 groups) were excluded from PKPS due to PK profiles being not consistent with the intravenous pharmacokinetics. Follow-up was conducted up to day 78 for the 2, 6 and 20 mg/kg cohorts in Study CHN Part 1 and the 2 mg/kg cohort in Study AUS. For all other cohorts in the two studies, follow-up was done up to day 43. ADAS, anti-drug antibody analysis set; AE, adverse event; PDS, pharmacodynamics analysis set; PK, pharmacokinetic; PKCS, PK concentration analysis set; PKPS, PK parameter analysis set; SS, safety set.

Table S1. Summary of treatment-emergent adverse events.

| | Placebo | SHR-1707 | | | | | |
|---|---|---|---|---|---|---|---|
| | | 2 mg/kg | 6 mg/kg | 20 mg/kg | 40 mg/kg | 60 mg/kg | Total |
| **Study CHN Part 1** | | | | | | | |
| Subject No. | 10 | 8 | 8 | 8 | 8 | 8 | 40 |
| AE | 9 (90.0) | 7 (87.5) | 4 (50.0) | 8 (100.0) | 5 (62.5) | 4 (50.0) | 28 (70.0) |
| Moderate or severe | 0 | 1 (12.5) | 0 | 1* (12.5) | 0 | 0 | 2 (5.0) |
| AE leading to treatment discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SAE | 0 | 0 | 0 | 1* (12.5) | 0 | 0 | 1 (2.5) |
| **Study CHN Part 2** | | | | | | | |
| Subject No. | 4 | – | – | 8 | – | – | 8 |
| AE | 2 (50.0) | – | – | 6 (75.0) | – | – | 6 (75.0) |
| Moderate or severe | 0 | – | – | 1 (12.5) | – | – | 1 (12.5) |
| AE leading to treatment discontinuation | 0 | – | – | 0 | – | – | 0 |
| SAE | 0 | – | – | 0 | – | – | 0 |
| **Study AUS** | | | | | | | |
| Subject No. | 6 | 8 | – | 8 | – | 8 | 24 |
| AE | 6 (100.0) | 8 (100.0) | – | 8 (100.0) | – | 8 (100.0) | 24 (100.0) |
| Moderate or severe | 2 (33.3) | 0 | – | 1 (12.5) | – | 0 | 1 (4.2) |
| AE leading to treatment discontinuation | 0 | 0 | – | 1 (12.5) | – | 0 | 1 (4.2) |
| SAE | 0 | 0 | – | 0 | – | 0 | 0 |

Data are n (%). AE, adverse event; SAE, serious adverse event. * One case of ectopic pregnancy was reported and was assessed as unlikely related to study treatment.